As global markets navigate the aftermath of the longest U.S. government shutdown in history, concerns about elevated valuations and artificial intelligence spending have prompted a shift away from growth-oriented stocks. In this environment, Asian markets are also feeling the ripple effects, making it crucial for investors to identify companies with strong fundamentals and high insider ownership as potential indicators of confidence and stability amidst volatility.
Top 10 Growth Companies With High Insider Ownership In Asia
| Name | Insider Ownership | Earnings Growth |
| Streamax Technology (SZSE:002970) | 32.5% | 33.1% |
| Seers Technology (KOSDAQ:A458870) | 33.9% | 79.1% |
| Oscotec (KOSDAQ:A039200) | 12.7% | 118.4% |
| Novoray (SHSE:688300) | 23.6% | 31.4% |
| Loadstar Capital K.K (TSE:3482) | 31% | 23.6% |
| Laopu Gold (SEHK:6181) | 34.8% | 34.3% |
| J&V Energy Technology (TWSE:6869) | 17.5% | 31.6% |
| Gold Circuit Electronics (TWSE:2368) | 31.4% | 31.1% |
| Fulin Precision (SZSE:300432) | 11.6% | 55.2% |
| Ascentage Pharma Group International (SEHK:6855) | 12.8% | 30.3% |
Let's take a closer look at a couple of our picks from the screened companies.
Shanghai Daimay Automotive Interior (SHSE:603730)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Shanghai Daimay Automotive Interior Co., Ltd focuses on the research, development, and sale of passenger car components both in China and internationally, with a market cap of CN¥16.82 billion.
Operations: Shanghai Daimay Automotive Interior Co., Ltd generates revenue through its involvement in the research, development, and sale of components for passenger vehicles across domestic and international markets.
Insider Ownership: 24.8%
Earnings Growth Forecast: 26.7% p.a.
Shanghai Daimay Automotive Interior shows potential as a growth company with high insider ownership. Despite recent declines in net income and earnings per share, the company is trading at a favorable price-to-earnings ratio of 27x compared to the CN market's 44.9x, suggesting good relative value. Revenue is forecast to grow at 17.6% annually, outpacing the CN market average of 14.4%, while earnings are expected to increase significantly over the next three years.
- Dive into the specifics of Shanghai Daimay Automotive Interior here with our thorough growth forecast report.
- The valuation report we've compiled suggests that Shanghai Daimay Automotive Interior's current price could be quite moderate.
Huatu Cendes (SZSE:300492)
Simply Wall St Growth Rating: ★★★★★☆
Overview: Huatu Cendes Co., Ltd. is an architectural design company offering professional design, consulting, and engineering services to various sectors in China, with a market cap of CN¥13.68 billion.
Operations: Huatu Cendes Co., Ltd. generates revenue through its architectural design, consulting, and engineering services provided to state-owned enterprises, multinational corporations, private companies, and government agencies in China.
Insider Ownership: 16.5%
Earnings Growth Forecast: 41.5% p.a.
Huatu Cendes demonstrates strong growth potential with earnings having grown substantially by 319.5% over the past year and forecasted to continue increasing at 41.52% annually, outpacing the CN market's average. Revenue is also expected to grow faster than the market at 19.7% per year, despite being slightly below the 20% threshold for high growth rates. Recent earnings reports show significant improvements in net income and sales, reinforcing its robust performance trajectory.
- Unlock comprehensive insights into our analysis of Huatu Cendes stock in this growth report.
- The analysis detailed in our Huatu Cendes valuation report hints at an inflated share price compared to its estimated value.
PeptiDream (TSE:4587)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: PeptiDream Inc. is a biopharmaceutical company focused on the discovery and development of constrained peptides, small molecules, and peptide-drug conjugate therapeutics, with a market cap of ¥216.56 billion.
Operations: PeptiDream generates revenue from its Radioactive Pharmaceutical Business, amounting to ¥16.77 billion, and its Drug Discovery and Development Business, which contributes ¥2.28 billion.
Insider Ownership: 25.7%
Earnings Growth Forecast: 31.4% p.a.
PeptiDream's growth trajectory is bolstered by its forecasted earnings increase of 31.44% annually, outpacing the Japanese market. While its revenue growth of 17.2% per year is slower than high-growth benchmarks, it still surpasses market averages. The company's strategic collaboration for a Phase 2 trial in Japan highlights innovation in prostate cancer diagnostics and therapeutics. Despite trading significantly below estimated fair value, PeptiDream's low future return on equity could be a concern for investors seeking high returns.
- Navigate through the intricacies of PeptiDream with our comprehensive analyst estimates report here.
- In light of our recent valuation report, it seems possible that PeptiDream is trading behind its estimated value.
Make It Happen
- Access the full spectrum of 622 Fast Growing Asian Companies With High Insider Ownership by clicking on this link.
- Contemplating Other Strategies? This technology could replace computers: discover the 26 stocks are working to make quantum computing a reality.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
Valuation is complex, but we're here to simplify it.
Discover if PeptiDream might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com